VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility
VarmX, a Dutch biotech developing a reversal agent for blood thinners, has bagged a €30 million Series B2 round as it gets ready to launch a pivotal trial.
LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round.
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer
VarmX – which focuses on the development of innovative approaches for the reversal of anticoagulation – has announced it will present new preclinical data on the pharmacodynamics, toxicokinetics and safety of VMX-C001.
LEIDEN, The Netherlands--(BUSINESS WIRE)--VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.
Leiden, The Netherlands, 19 July 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral presentation at the ISTH (International Society on Thrombosis and Haemostasis) Virtual Congress on Tuesday, 20 July, 2021 at 11.00-12.00 EDT.